These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 33917243)

  • 21. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
    J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
    Kassi FK; Bellet V; Drakulovski P; Krasteva D; Roger F; Valérie BA; Aboubakar T; Doumbia A; Kouakou GA; Delaporte E; Reynes J; Yavo W; Menan HIE; Bertout S
    J Med Microbiol; 2018 Jan; 67(1):87-96. PubMed ID: 29214970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
    Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
    Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].
    Favalessa OC; Ribeiro LC; Tadano T; Fontes CJ; Dias FB; Coelho BP; Hahn RC
    Rev Soc Bras Med Trop; 2009; 42(6):661-5. PubMed ID: 20209351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-γ promotes phagocytosis of Cryptococcus neoformans but not Cryptococcus gattii by murine macrophages.
    Ikeda-Dantsuji Y; Ohno H; Tanabe K; Umeyama T; Ueno K; Nagi M; Yamagoe S; Kinjo Y; Miyazaki Y
    J Infect Chemother; 2015 Dec; 21(12):831-6. PubMed ID: 26477011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
    Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
    J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of cryptococcosis in and around Chandigarh, India, during the period 1982-91.
    Chander J; Sapra RK; Talwar P
    Mycoses; 1994; 37(1-2):23-6. PubMed ID: 7935587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Susceptibility to antifungal agents of Cryptococcus species of clinical interest].
    García-Martos P; Noval JF; García-Tapia A; Marín P; Puerto JL; Sepúlveda A
    Med Clin (Barc); 2002 Jul; 119(6):211-3. PubMed ID: 12200008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antifungal susceptibility profiles of Cryptococcus species isolated from HIV-associated cryptococcal meningitis patients in Zimbabwe.
    Nyazika TK; Herkert PF; Hagen F; Mateveke K; Robertson VJ; Meis JF
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):289-292. PubMed ID: 27608538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
    Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii.
    De Bedout C; Ordóñez N; Gómez BL; Rodríguez MC; Arango M; Restrepo A; Castañeda E
    Rev Iberoam Micol; 1999 Mar; 16(1):36-9. PubMed ID: 18473590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India.
    Khan ZU; Randhawa HS; Kowshik T; Chowdhary A; Chandy R
    J Antimicrob Chemother; 2007 Aug; 60(2):312-6. PubMed ID: 17553813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined antifungal therapy against systemic murine infections by rare Cryptococcus species.
    Thomson P; Mayayo E; López-Fernández L; Guarro J; Capilla J
    Mycoses; 2017 Feb; 60(2):112-117. PubMed ID: 27696562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro susceptibility of Chilean Cryptococcus neoformans strains of clinical source].
    Cruz Ch R; Vieille O P; Stojanova J
    Rev Chilena Infectol; 2020 Apr; 37(2):124-128. PubMed ID: 32730477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiological, Epidemiological, and Clinical Characteristics of Patients With Cryptococcal Meningitis at a Tertiary Hospital in China: A 6-Year Retrospective Analysis.
    Li Y; Zou M; Yin J; Liu Z; Lu B
    Front Microbiol; 2020; 11():1837. PubMed ID: 32849436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
    Lahiri Mukhopadhyay S; Bahubali VH; Manjunath N; Swaminathan A; Maji S; Palaniappan M; Parthasarathy S; Chandrashekar N
    Mycoses; 2017 Nov; 60(11):749-757. PubMed ID: 28736880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil.
    Damasceno-Escoura AH; de Souza ML; de Oliveira Nunes F; Pardi TC; Gazotto FC; Florentino DH; Mora DJ; Silva-Vergara ML
    Mycopathologia; 2019 Feb; 184(1):65-71. PubMed ID: 30415450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.